12-May-2026
Bio-Techne Insider Move: Major Director Stock Sale Raises Eyebrows on Wall Street
TipRanks (Tue, 12-May 10:15 PM ET)
Notable healthcare headlines for the week: UnitedHealth, Pfizer, and CVS Health in focus
Seeking Alpha News (Sun, 10-May 9:05 AM ET)
Most healthcare companies report higher Y/Y EPS in strong earnings week
Seeking Alpha News (Sat, 9-May 11:30 AM ET)
PRNewswire (Wed, 6-May 5:21 PM ET)
Bio-Techne Releases Third Quarter Fiscal 2026 Results
PRNewswire (Wed, 6-May 5:20 PM ET)
Bio-Techne to Present at the Bank of America Securities 2026 Global Healthcare Conference
PRNewswire (Mon, 4-May 7:00 AM ET)
PRNewswire (Tue, 14-Apr 7:05 AM ET)
Bio-Techne Advances Spatial Biology with Modular Expansion of COMET Suite
PRNewswire (Wed, 25-Mar 6:30 AM ET)
Bio-Techne to Present at Upcoming Investor Conferences
PRNewswire (Tue, 24-Feb 7:00 AM ET)
PRNewswire (Mon, 16-Feb 6:30 AM ET)
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Bio-Techne trades on the NASDAQ stock market under the symbol TECH.
As of May 12, 2026, TECH stock price was flat at $47.42 with 1,672,322 million shares trading.
TECH has a beta of 1.19, meaning it tends to be more sensitive to market movements. TECH has a correlation of 0.12 to the broad based SPY ETF.
TECH has a market cap of $7.38 billion. This is considered a Mid Cap stock.
Last quarter Bio-Techne reported $311 million in Revenue and $.53 earnings per share. This fell short of revenue expectation by $-5 million and exceeded earnings estimates by $.01.
In the last 3 years, TECH traded as high as $89.91 and as low as $45.12.
The top ETF exchange traded funds that TECH belongs to (by Net Assets): VTI, VOO, VB, RSP, VBK.
TECH has underperformed the market in the last year with a price return of -4.4% while the SPY ETF gained +32.1%. TECH has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -25.1% and -14.0%, respectively, while the SPY returned +6.9% and +3.2%, respectively.
TECH support price is $45.90 and resistance is $48.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TECH shares will trade within this expected range on the day.